EP0735821A4 - Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amylo dogenes - Google Patents

Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amylo dogenes

Info

Publication number
EP0735821A4
EP0735821A4 EP95906018A EP95906018A EP0735821A4 EP 0735821 A4 EP0735821 A4 EP 0735821A4 EP 95906018 A EP95906018 A EP 95906018A EP 95906018 A EP95906018 A EP 95906018A EP 0735821 A4 EP0735821 A4 EP 0735821A4
Authority
EP
European Patent Office
Prior art keywords
reptides
amyloidogenic
prevention
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95906018A
Other languages
German (de)
English (en)
Other versions
EP0735821A1 (fr
Inventor
William Henry Walker Lunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0735821A1 publication Critical patent/EP0735821A1/fr
Publication of EP0735821A4 publication Critical patent/EP0735821A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP95906018A 1993-12-21 1994-12-14 Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amylo dogenes Withdrawn EP0735821A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17154693A 1993-12-21 1993-12-21
US171546 1993-12-21
PCT/US1994/014655 WO1995017095A1 (fr) 1993-12-21 1994-12-14 Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amyloïdogenes

Publications (2)

Publication Number Publication Date
EP0735821A1 EP0735821A1 (fr) 1996-10-09
EP0735821A4 true EP0735821A4 (fr) 1998-04-01

Family

ID=22624148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95906018A Withdrawn EP0735821A4 (fr) 1993-12-21 1994-12-14 Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amylo dogenes

Country Status (6)

Country Link
EP (1) EP0735821A4 (fr)
JP (1) JPH09507071A (fr)
AU (1) AU1440395A (fr)
CA (1) CA2176127A1 (fr)
WO (1) WO1995017095A1 (fr)
ZA (1) ZA9410036B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
EP0716854A3 (fr) * 1994-10-20 1996-08-28 Lilly Co Eli Compositions pour inhiber le récepteur de la neuropeptide Y
CA2206752A1 (fr) * 1996-07-02 1998-01-02 George Joseph Cullinan Composes de benzothiophene,intermediaires, procedes et methodes d'utilisation
WO1998022441A2 (fr) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. ESTERS DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES ET METHODES POUR INHIBER LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU SA SYNTHESE
US5965614A (en) * 1996-11-22 1999-10-12 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1998046588A2 (fr) 1997-04-11 1998-10-22 Neorx Corporation Composes et therapies destines a la prevention d'affections vasculaires ou non vasculaires
ATE286395T1 (de) 1997-04-30 2005-01-15 Lilly Co Eli Antithrombotische mittel
WO1998049160A1 (fr) 1997-04-30 1998-11-05 Eli Lilly And Company Agents antithrombotiques
EP0973517A4 (fr) 1997-04-30 2002-07-24 Lilly Co Eli Agents antithrombotiques
CA2287993A1 (fr) 1997-04-30 1998-11-05 Mary George Johnson Agents antithrombotiques
EP0988289A2 (fr) * 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Composes heterocycliques, leur preparation et leur utilisation
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
AU3171099A (en) * 1998-04-17 1999-11-08 Senga Pharmaceutical Laboratory Inc. 1-heteroindene derivatives and medicinal composition containing the same
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
SK18812000A3 (sk) * 1998-06-16 2002-01-07 Eli Lilly And Company Spôsoby zvyšovania hladín acetylcholínu
JP2002518329A (ja) * 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
DK0997460T3 (da) * 1998-10-28 2003-03-31 Lilly Co Eli Benzothiophenforbindelser som antithrombotiske midler og mellemprodukter
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
MXPA05013975A (es) * 2003-06-23 2006-03-09 Neurochem Int Ltd Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
KR100858357B1 (ko) * 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
JP2008231102A (ja) * 2007-02-23 2008-10-02 Hiroaki Okuno アミロイドベータ凝集阻害作用を有するフェノール誘導体
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
EP0617030A1 (fr) * 1993-03-19 1994-09-28 Eli Lilly And Company Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes
WO1994023708A1 (fr) * 1993-04-10 1994-10-27 Altramed Holdings Ltd. Utilisation d'antagonistes steroïdiens pour le traitement et la prophylaxie de maladies du type demence
WO1995017382A1 (fr) * 1993-12-21 1995-06-29 Eli Lilly And Company Antagonistes non peptidiques des recepteurs des tachykinines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024273A (en) * 1974-06-20 1977-05-17 Smithkline Corporation Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
US5185350A (en) * 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
EP0617030A1 (fr) * 1993-03-19 1994-09-28 Eli Lilly And Company Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes
WO1994023708A1 (fr) * 1993-04-10 1994-10-27 Altramed Holdings Ltd. Utilisation d'antagonistes steroïdiens pour le traitement et la prophylaxie de maladies du type demence
WO1995017382A1 (fr) * 1993-12-21 1995-06-29 Eli Lilly And Company Antagonistes non peptidiques des recepteurs des tachykinines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9517095A1 *

Also Published As

Publication number Publication date
EP0735821A1 (fr) 1996-10-09
ZA9410036B (en) 1996-06-18
AU1440395A (en) 1995-07-10
WO1995017095A1 (fr) 1995-06-29
JPH09507071A (ja) 1997-07-15
CA2176127A1 (fr) 1995-06-29

Similar Documents

Publication Publication Date Title
AU1440395A (en) Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
EP0814814A4 (fr) Methodes de traitement de la thrombose
AU7545594A (en) Implantable device for the treatment of aedemas
HU9503451D0 (en) The treatment of small animals
ZA942809B (en) Treatment
EP0674707A4 (fr) Composes et methodes de traitement des leucemies.
GB9203039D0 (en) Treatment
EP0642337A1 (fr) Dapsone et promine pour le traitement de la maladie d'alzheimer.
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
IL111790A0 (en) Methods of inhibiting the effects of amyloidogenic proteins
EP0505086A3 (en) Method for the treatment of lamellar or plate-like materials
CY2375B1 (en) Use of penciclorin for the treatment of post-therapeutic neuralgia.
GR3024856T3 (en) Process for the preparation of dichloroacetylchloride.
GB2279070B (en) Process for the treatment of sewage
GB2306096B (en) The treatment of small animals
GB9323550D0 (en) Composition for the treatment of hydrothyroidism
BG98002U (en) Medicament for the treatment of seborrheic conditions
CA73431S (en) Tub or the like
ZA948336B (en) Treatment
GB9310836D0 (en) Treatment
GB9311351D0 (en) The treatment of small animals
GB9202770D0 (en) Enzymatic treatment
SG49291A1 (en) Use of penciclorin for the treatment of post-therapeutic neuralgia
CA69839S (en) Bowl or the like
CA71752S (en) Bowl or the like

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960621;SI PAYMENT 960621

RAX Requested extension states of the european patent have changed

Free format text: LT PAYMENT 960621;SI PAYMENT 960621

A4 Supplementary search report drawn up and despatched

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000219